8-K: LivaNova Announces Proposed $300 Million Convertible Senior Notes Offering

LivaNova PLC plans to offer $300 million in convertible senior notes due 2029 in a private placement to qualified institutional buyers.

Summary

• LivaNova PLC has announced a proposed private offering of $300 million in convertible senior notes due in 2029.
• The notes will be offered to qualified institutional buyers and are subject to market conditions.
• Initial purchasers will have an option to buy an additional $45 million in notes.
• The notes are senior, unsecured obligations of LivaNova.
• The notes will be convertible under certain conditions, with LivaNova having the option to settle conversions in cash, shares, or a combination of both.
• LivaNova may redeem the notes on or after March 22, 2027, if its share price reaches 130% of the conversion price.
• The company also plans to enter into capped call transactions to mitigate potential dilution from the note conversions.
• LivaNova is considering repurchasing a portion of its 3.00% Cash Exchangeable Senior Notes due 2025.
• The company intends to use the net proceeds for capped call transactions, note repurchases, and general corporate purposes.
• LivaNova is also in negotiations to amend its existing credit agreement to increase the available amount and decrease the margin.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the offering provides capital, it also introduces potential dilution and market risks. The capped call transactions and potential debt repurchase are positive mitigations.

Positives

• The offering provides LivaNova with a significant amount of capital, potentially up to $345 million if the option is exercised.
• The capped call transactions are designed to mitigate potential dilution from the convertible notes.
• The potential repurchase of existing notes could reduce LivaNova's debt obligations.
• The amendment to the credit agreement could improve LivaNova's financial flexibility.
• The company has the flexibility to settle conversions in cash, shares, or a combination of both.

Negatives

• The convertible notes could lead to dilution of existing shareholders if converted to shares.
• The market price of LivaNova's shares could be affected by the hedging activities of the option counterparties.
• The terms of the notes, including the interest rate and conversion rate, are yet to be determined.
• There is no guarantee that the credit agreement amendment will be completed.
• The repurchase of the 2025 notes is not guaranteed and depends on negotiations with each holder.

Risks

• The offering is subject to market conditions and may not be completed.
• The conversion of the notes could dilute existing shareholders.
• Hedging activities related to the capped call transactions could impact the share price.
• The company's share price must reach 130% of the conversion price for the notes to be redeemable.
• The company may not be able to complete the credit agreement amendment.
• The repurchase of the 2025 notes is not guaranteed and depends on negotiations with each holder.

Future Outlook

LivaNova intends to use the net proceeds from the offering for capped call transactions, note repurchases, and general corporate purposes, and is also seeking to amend its credit agreement to increase the available amount and decrease the margin.

Management Comments

• LivaNova announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029.
• LivaNova also intends to grant to the initial purchasers of the notes an option to purchase up to an additional $45 million aggregate principal amount of the notes.
• LivaNova expects to use the net proceeds of the offering to pay the cost of the capped call transactions, to pay the cost of the note repurchases, and for general corporate purposes.

Industry Context

This announcement is typical for companies seeking to raise capital through debt financing, particularly convertible notes, which can be attractive to investors due to their potential for equity upside. The use of capped call transactions is also a common strategy to mitigate dilution.

Comparison to Industry Standards

• The use of convertible notes is a common financing method in the medical technology industry, with companies like Medtronic and Boston Scientific having used similar instruments in the past.
• The size of the offering, $300 million, is within the range of typical convertible note offerings by mid-sized medical device companies.
• The inclusion of capped call transactions is a standard practice to manage potential dilution, similar to what other companies in the sector have done.
• The potential repurchase of existing notes is a strategic move to manage debt obligations, which is also seen in other companies in the industry.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted to shares.
• Noteholders will have the potential to convert their notes into shares or receive cash.
• The company's financial flexibility may improve with the new capital and potential credit agreement amendment.
• The market price of LivaNova's shares could be affected by the offering and related hedging activities.

Next Steps

• LivaNova will proceed with the private offering of the convertible senior notes.
• The company will negotiate the terms of the notes, including the interest rate and conversion rate.
• LivaNova will enter into capped call transactions with the initial purchasers.
• The company will negotiate potential repurchases of its 3.00% Cash Exchangeable Senior Notes due 2025.
• LivaNova will continue negotiations to amend its existing credit agreement.

Key Dates

Keywords

convertible notes, senior notes, private offering, capped call, note repurchase, dilution, LivaNova, debt, financing, credit agreement